Cortisol As a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas
Overview
Affiliations
Context: Incidental benign adrenocortical adenomas, adrenal incidentalomas are found in 4.5% of abdominal computed tomography scans, with the incidence increasing to 10% in patients older than 70 years of age. These incidentalomas frequently show evidence of excess cortisol secretion but without overt Cushing's syndrome. The mortality rate is increased in Cushing's syndrome.
Objective: This study sought to investigate whether patients with adrenal incidentalomas have an increased mortality.
Design: This was a retrospective, longitudinal cohort study.
Setting: The study was carried out in an Endocrine Investigation Unit in a University Teaching Hospital.
Patients: Two hundred seventy-two consecutive patients with an incidental adrenal mass underwent a dedicated diagnostic protocol, which included dexamethasone testing for hypercortisolism between 2005 and 2013. Overall survival was assessed in 206 patients with a benign, adrenocortical adenoma.
Main Outcome Measures: Survival analysis was carried out by using Kaplan-Meier curves and the effect of dexamethasone cortisol estimated by Cox-regression analysis. Cause-specific mortality was ascertained from death certificates and compared with local and national data.
Results: Eighteen of 206 patients died and the mean time (SD) from diagnosis to death was 3.2 (1.7) years. Seventeen of 18 patients who died had a post dexamethasone cortisol >1.8 μg/dL and there was a significant decrease in survival rate with increasing dexamethasone cortisol levels (P = .001). Compared with the <1.8 μg/dL group, the hazard ratio (95% confidence interval) for the 1.8-5 μg/dL group was 12.0 (1.6-92.6) whereas that of the >5 μg/dL group was 22.0 (2.6-188.3). Fifty percent and 33% of deaths were secondary to circulatory or respiratory/infective causes, respectively.
Conclusions: PATIENTS with adrenal incidentalomas and a post-dexamethasone serum cortisol >1.8 μg/dL have increased mortality, mainly related to cardiovascular disease and infection.
Meric C, Tasci I, Akin S, Candemir B, Guzel Esen S, Dag Z Am J Transl Res. 2024; 16(11):6679-6688.
PMID: 39678618 PMC: 11645597. DOI: 10.62347/JTQX7232.
Zhao X, Zhou J, Lyu X, Li Y, Ma L, Liu Y Sci Rep. 2024; 14(1):23557.
PMID: 39384846 PMC: 11464552. DOI: 10.1038/s41598-024-74452-y.
Favero V, Parazzoli C, Bernasconi D, Chiodini I J Endocrinol Invest. 2024; 47(12):2929-2942.
PMID: 39347906 PMC: 11549128. DOI: 10.1007/s40618-024-02440-0.
Patrova J, Mannheimer B, Larsson M, Lindh J, Falhammar H J Endocr Soc. 2024; 8(10):bvae154.
PMID: 39301313 PMC: 11411210. DOI: 10.1210/jendso/bvae154.
Ren X, Nan M, Zhang X Front Endocrinol (Lausanne). 2024; 15():1399311.
PMID: 39086899 PMC: 11288901. DOI: 10.3389/fendo.2024.1399311.